Clinical Trial Update: A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase I trial evaluating ovarian cancer peptides plus GM-CSF as adjuvant therapy for epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• GM-CSF (sargramostim) (granulocyte-monocyte colony-stimulating factor)
• Ovarian cancer peptides (unidentified)

Snippet

Sponsor: Michael Morse, MD | Conditions: Epithelial Ovarian, Tubal or Peritoneal Cancer | Phase 1 | Status: COMPLETED